GlassScriptPhysician profile
Leticia S Hernandez
NPI 1417038555
$3,671.43
in general payments reported to CMS, 2019-2025
27 companies · $486 in 2025
The $486 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,103 · 2020: $397 · 2021: $1,016 · 2022: $317 · 2023: $230 · 2024: $123 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $838.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $869.69 | 2019-2025 | |
| Therapeuticsmd, INC. | $494.85 | 2019-2021 | |
| Pfizer INC. | $241.41 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $238.39 | 2021-2025 | |
| Avion Pharmaceuticals | $236.06 | 2019-2023 | Balcoltra |
| Biogen, INC. | $196.56 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $182.42 | 2020-2025 | Myosure Tissue Removal Device, Fluent Fluid Management System |
| Duchesnay USA Incorporated | $167.30 | 2019 | |
| Intuitive Surgical, INC. | $160.23 | 2019 | |
| Organon LLC | $138.93 | 2021-2023 | Nexplanon |
| Myovant Sciences INC. | $136.02 | 2021 | |
| Radius Health, INC. | $130.01 | 2019 | |
| Shield Therapeutics INC | $80.41 | 2023-2025 | Accrufer |
| Agile Therapeutics, INC. | $55.69 | 2022-2023 | Twirla |
| Exeltis, USA INC. | $50.88 | 2023-2025 | Slynd |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $42.73 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.27 | 2019-2025 | |
| Sage Therapeutics, LLC | $34.73 | 2025 | Zurzuvae |
| Allergan, INC. | $31.13 | 2019 | |
| Lupin INC. | $28.77 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $20.47 | 2019 | |
| Aspira Women'S Health INC | $18.62 | 2024 | Ova1 |
| Minerva Surgical, INC | $18.28 | 2025 | |
| Grifols USA, LLC | $17.41 | 2021 | |
| Sumitomo Pharma America, INC. | $14.67 | 2024 | Myfembree |
| Coopersurgical, INC. | $14.07 | 2021 | |
| Davol INC. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leticia Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.